Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines. Nakayama H, Saito N, Kasajima R, Suganuma N, et al. Anticancer Res 2023;43:1073-1077.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nakayama H, Saito N, Kasajima R, Suganuma N, et al. Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines. Anticancer Res 2023;43:1073-1077.
PMID: 36854530